Today, members of the Heart Rhythm Society (HRS) are visiting 35 congressional offices on Capitol Hill to raise visibility and support for two proposals: the “Medicare Program Integrity Improvement and Education Act” and the “Teaching Children to Save Lives Act.” HRS is advocating for the support of these two bills because both intend to deliver outcomes aligned with the Society’s mission to improve the care of patients by advancing research, education and optimal health care policies and standards. 

A lot of warfarin 2 mg tablets is under recall for being oversized.

The drug development pipeline for cardiovascular medicines runneth over, according to a report by PhRMA. Still, that may translate into only a few new products.

ATLANTA—Opportunities exist within many cardiovascular programs to trim out costs and add value. But where? Suzette Jaskie, president and CEO of MedAxiom Consulting, offered five “slam dunk” approaches June 13 at the Cardiovascular Service Line Symposium in Atlanta.

The FDA approved next-generation implantable defibrillators that offer new safety and performance features.

The use of radial PCI in the U.S. increased 13-fold between 2007 and 2012, according to an analysis published June 11 in Circulation. But operators appeared less likely to apply the approach in patients at high risk of bleeding and vascular complications, a subgroup that might benefit the most.

A pharmaceutical used to treat early-stage Alzheimer’s disease may help reduce the risk of MI and death, according to a study published June 5 in the European Heart Journal.

Vascular surgeon Jeffrey H. Lawson, MD, PhD, implanted a bioengineered vein graft June 5 in a patient with end-stage kidney disease in a two-hour procedure at Duke University Hospital in Durham. The operation launches the U.S. trial of the human cell-based product that Lawson helped develop. If the bioengineered veins prove beneficial for hemodialysis patients, then they may try to develop a graft for heart bypass surgeries.